Immunization of children with inflammatory bowel disease against SARS-CoV-19 infection: A prospective single centre cohort study

Dóra Dohos; Anna Karoliny; Eszter Gombos; Éva Rimanóczy; Katalin E Müller

doi:10.1016/j.jvacx.2023.100374

Immunization of children with inflammatory bowel disease against SARS-CoV-19 infection: A prospective single centre cohort study

Vaccine X. 2023 Aug 19:15:100374. doi: 10.1016/j.jvacx.2023.100374. eCollection 2023 Dec.

Authors

Dóra Dohos^{1

2}, Anna Karoliny², Eszter Gombos², Éva Rimanóczy², Katalin E Müller^{2

3}

Affiliations

¹ Institute for Translational Medicine, Medical School, University of Pécs, Pécs, Hungary.
² Heim Pál National Pediatric Institute, Budapest, Hungary.
³ Department of Family Care Methodology, Faculty of Health Science, Semmelweis University, Budapest, Hungary.

Abstract

Background: Real-world data of children with inflammatory bowel disease (IBD) after SARS-CoV-2 vaccination are needed.

Method: This prospective, observational study evaluate antibody kinetics of children with IBD 6 months after immunization with COVID-19 mRNA vaccine.

Results: 24 children with IBD were included, 22 received immunosuppressive treatment. After five weeks the spike protein antibody level was positive in 95% of the cases. After six months all participants had seropositivity results, though the titre was decreasing.

Conclusion: These data show the effectiveness of SARS-CoV2 immunization and the antibody decay over time, that highlight the importance of booster vaccines.

Keywords: COVID-19 infection; Children; IBD; Immunization; SARS-CoV2 immunization.